Alexion Pharmaceuticals Stock News

AstraZeneca has agreed to buy U.S. Alexion Pharmaceuticals for $39 billion, betting on rare diseases and immunology as the British drug company emerges as one of the leading developers of a COVID-19 v

Alexion Pharmaceuticals soared 35% in pre-market trading on Monday after AstraZeneca announced a $39 billion acquisition of the Boston-based drugmaker. The deal was approved by both boards unanimously

Shares of AstraZeneca fell 8% early on Monday, hit by doubts about the British firm's strategy and speculation of a rival bid after it announced the $39 billion purchase of Alexion Pharmaceuticals ove

SAN DIEGO, Dec. 13, 2020 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Alexion Pharmaceuticals, Inc. ("Alexion" or the

AstraZeneca plc (NASDAQ: AZN) announced it is buying Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) for $39 billion in cash and shares. These are the details.

AstraZeneca has announced its acquiring Alexion at a fairly substantial 45% premium. It's a mixed stock - cash offer. The synergies will cover most of the ~$900 million in annual dividend / interest c

AstraZeneca plc (LON: AZN) said on Saturday that it will buy Alexion Pharmaceuticals (NASDAQ: ALXN) for £29.50 billion. The acquisition marks the largest for the British pharmaceutical giant in histo

At $39 billion, AstraZeneca is low-balling its bid for Alexion -- maker of Soliris, a drug that sells for $678,302 a year

Leading Covid-19 vaccine developer AstraZeneca agreed on Saturday to buy Boston pharmaceutical firm Alexion for $39 billion.

Alexion shareholders will receive a big premium in a combination of cash and AstraZeneca stock.

AstraZeneca plc (NASDAQ: AZN)has announced it will buy Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), a Boston-based drugmaker, for $39 billion. What Happened: British pharmaceutical company AstraZenec

AstraZeneca on Saturday announced it was acquiring Alexion Pharmaceuticals in a $39 billion deal,  a move intended to boost AstraZeneca's immunology research and combine the company's delivery pipeli

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) to AstraZeneca PLC for $60.00 in cash

AstraZeneca Plc will acquire U.S. based Alexion Pharmaceuticals in a $39 billion deal, the company said in a statement on Saturday.

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--AstraZeneca to acquire Alexion, accelerating the Company's strategic and financial development